The Effect of Combined Therapy ICS/LABA and ICS/LABA plus Montelukast in Patients with Uncontrolled Severe Persistent Asthma Based on the Serum IL-13 and FEV1

Elena Jovanovska Janeva; Zlatica Goseva; Angjelko Gjorchev; Angela Debreslioska; Mirko Spiroski; Beti Zafirova; Magdalena Genadieva Dimitrova

doi:10.3889/oamjms.2015.053

Authors

Elena Jovanovska Janeva University Clinic of Pulmonology and Allergology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
Zlatica Goseva University Clinic of Pulmonology and Allergology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
Angjelko Gjorchev University Clinic of Pulmonology and Allergology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
Angela Debreslioska University Clinic of Pulmonology and Allergology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
Mirko Spiroski Institute of Immunobiology and Human Genetics, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
Beti Zafirova Institute of Epidemiology and Biostatistics, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
Magdalena Genadieva Dimitrova University Clinic of Gastroenterohepatology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje

DOI:

https://doi.org/10.3889/oamjms.2015.053

Keywords:

asthma, IL-13, FEV1, ICS/LABA, Montelukast

Abstract

BACKGROUND: IL-13 is one of many cytokines responsible for the chronic inflammation of asthma.

AIM: The aim of this study was to determine the effect of combined therapy ICS/LABA and ICS/LABA plus Montelukast in patients with uncontrolled severe persistent asthma by analyzing of serum IL-13 and FEV1 before the treatment and after 6 months of therapy.

MATERIAL AND METHODS: In study we included two groups. First group with 27 patients were treated with ICS/LABA. Second group with 29 patients were treated with ICS/LABA plus Montelukast. In each of them were measured serum IL-13 levels by the ELISA method and FEV1 before and after 6 months of treatment. Results were statistically analyzed according to the Wilcoxon Pairs Test and T-test.

RESULTS: The obtained results in both groups showed that the serum IL-13 before the start of therapy were much higher and after 6 months of treatment significantly reduces their value, which in the second group were more expressed. The difference in the average value of FEV1 in both groups before and after therapy was statistically significant.

CONCLUSION: Treatment with ICS/LABA plus Montelukast proved superior compared to therapy of ICS/LABA in patients with uncontrolled severe persistent asthma and allows achievement of well controlled of asthma with subjective clinical improvement.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Global Initiative for Asthma (GINA), GINA Report 2014, Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org. Updated 2014.

World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach, 2007.

World Allergy Organization (WAO) White Book on Allergy, 2011.

Centers for Disease Control and Prevention. National Vital Statistics Reports. 2013;61(4).

Gjorcev A. Macedonian National Consensus for Diagnosis and Treatment of Asthma - Reality and Perspective, 1996

Cvetanov V. Allergic Diseases in R. Macedonia, 2006;151-174.

Postma DS, Timens W. Remodeling in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(5):434-9. DOI: https://doi.org/10.1513/pats.200601-006AW

Grainge CL, Lau LC, Ward JA, Dulay V, Lahiff G, Wilson S, Holgate S, Davies DE, Howarth PH. Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med. 2011;364(21):2006-15. DOI: https://doi.org/10.1056/NEJMoa1014350

Barnes PJ. Pathophysiology of asthma. Eur Respir Mon. 2003; 23:84â€“113.

Kuipers H, Lambrecht BN. The interplay of dendritic cells, Th2 cells and regulatory T cells in asthma. Curr Opin Immunol. 2004;16(6):702-8. DOI: https://doi.org/10.1016/j.coi.2004.09.010

Abbas AK, Lichtman Ah, Pober JS. Cellular and Molecular Immunology, 4nd ed., 2000: 235-69.

Roitt IM, and Delves PJ. Essential Immunology, 10th ed., 2001: 177-199.

Bart N. Lambrecht, Henk C. Hoogsteden, Zuzana Diamant. The immunological basis of asthma. Lung Biology in Health & Disease. 2003;174: 53-73. DOI: https://doi.org/10.3109/9780203911914

Larche M, Robinson DS, Kay AB. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol. 2003; 111:450â€“463. DOI: https://doi.org/10.1067/mai.2003.169

Miyahara N, Swanson BJ, Takeda K, et al. Effector CD8(+) T cells mediate inflammation and airway hyperresponsiveness. Nat Med. 2004;10:865â€“869. DOI: https://doi.org/10.1038/nm1081

Zhu J, Hidehiro Y, William EP. Differentiation of effectorsâ€™ CD4 T cell populations. Ann Rev Immunol. 2010; 28: 445â€“489. DOI: https://doi.org/10.1146/annurev-immunol-030409-101212

Wills-Karp M, Chiaramonte M. Interleukin-13 in asthma. Curr Opin Pulm Med. 2003;9:21-27. DOI: https://doi.org/10.1097/00063198-200301000-00004

Kraft M. Asthma Phenotypes and Interleukin-13 â€” Moving Closer to Personalized Medicine. N Engl J Med. 2011; 365:1141-1144. DOI: https://doi.org/10.1056/NEJMe1108666

National Institutes of Health. National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Accessed: January 1, 2009.

Clinical Pulmonary Function Testing, Exercise Testing, and Disability Evaluation. In Chest Medicine: Essentials Of Pulmonary And Critical Care Medicine. 5th edition. Editors: George RB, Light RW, Matthay RA, Matthay MA. May 2005.

Virchow JC, Mehta A, Ljungblad L, Mitfessel H; MONICA study group. Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: the MONtelukast In Chronic Asthma (MONICA) study. Respir Med. 2010;104(5):644-51. DOI: https://doi.org/10.1016/j.rmed.2009.11.022

Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ. 2003;327:891. DOI: https://doi.org/10.1136/bmj.327.7420.891

Joos S, Miksch A, Szecsenyi J, et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma:a systematic review. Thorax. 2008;63:453-62. DOI: https://doi.org/10.1136/thx.2007.081596

Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James IG, Konstantopoulos S, Rojas R, van Noord JA, Pons M, Gilles L, Leff JA; Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy (COMPACT) International Study Group. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax. 2003;58(3):211-6. DOI: https://doi.org/10.1136/thorax.58.3.211

Humbert M, Durham SR, Kimmitt P, Powell N, Assoufi B, Pfister R, Menz G, Kay AB, Corrigan CJ. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol. 1997;99(5):657-65. DOI: https://doi.org/10.1016/S0091-6749(97)70028-9

Shimbori C, Shiota N, Okunishi H. Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Eur J Pharmacol. 2011;650(1):424-30. DOI: https://doi.org/10.1016/j.ejphar.2010.09.084

Hanania NA. Targeting Airway Inflammation in Asthma: Current and Future Therapies. Chest. 2008; 133:989â€“998. DOI: https://doi.org/10.1378/chest.07-0829

Keith PK, Koch C, Djandji M, et al. Montelukast as add-on therapy with inhaled corticosteroids or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (The RADAR Trial). Respir J. 2009;16:17A-24A. DOI: https://doi.org/10.1155/2009/145071

Bozek A, Warkocka-Szoltysek B, Filipowska-Gronska A, Jarzab J. Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients. J Asthma. 2012;49(5):530-4. DOI: https://doi.org/10.3109/02770903.2012.680638

Vaquerizo MJ, Casan P, Castillo J, PerpiÃ±a M, Sanchis J, Sobradillo V, Valencia A, Verea H, Viejo JL, Villasante C, Gonzalez-Esteban J, Picado C; CASIOPEA (Capacidad de Singulair Oral en la Prevencion de Exacerbaciones Asmaticas) Study Group. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax. 2003 Mar;58(3):204-10. Erratum in: Thorax. 2003;58(4):370. DOI: https://doi.org/10.1136/thorax.58.3.204

Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, Zhang J, Reiss TF. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med. 1999;160(6):1862-8. DOI: https://doi.org/10.1164/ajrccm.160.6.9803042

Deykin A, Wechsler ME, Boushey HA, Chinchilli VM, Kunselman SJ, Craig TJ, DiMango E, Fahy JV, Kraft M, Leone F, Lazarus SC, Lemanske RF Jr, Martin RJ, Pesola GR, Peters SP, Sorkness CA, Szefler SJ, Israel E; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma. Am J Respir Crit Care Med. 2007;175(3):228-34. DOI: https://doi.org/10.1164/rccm.200601-112OC

Fish JE, Israel E, Murray JJ, Emmett A, Boone R, Yancey SW, Rickard KA. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest. 2001;120(2):423-30. DOI: https://doi.org/10.1378/chest.120.2.423

Paggiaro P, Bacci E. Montelukast in asthma: a review of its efficacy and place in therapy. Ther Adv Chronic Dis. 2011;2(1):47-58. DOI: https://doi.org/10.1177/2040622310383343

Dupont L, Potvin E, Korn D, Lachman A, Dramaix M, Gusman J, PechÃ© R; Singulair as Complementary Therapy to Fixed Association in Real life Study Group. Improving asthma control in patients suboptimally controlled on inhaled steroids and long-acting beta2-agonists: addition of montelukast in an open-label pilot study. Curr Med Res Opin. 2005;21(6):863-9. DOI: https://doi.org/10.1185/030079905X46304

Virchow Jr JC, Prasse A, Naya I, Summerton L, Harris A. Zafirlukast improves asthma control in patients receiving highdose inhaled corticosteroids. Am J Respir Crit Care Med. 2000; 162:578-85. DOI: https://doi.org/10.1164/ajrccm.162.2.9905041

Bisgaard H, Skoner D, Boza ML, Tozzi CA, Newcomb K, Reiss TF, Knorr B, Noonan G. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol. 2009;44(6):568-79. DOI: https://doi.org/10.1002/ppul.21018

Ducharme FM. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patientâ€™s withasthma: Systematic review of current evidence. BMJ. 2002; 324: 1545-1552. DOI: https://doi.org/10.1136/bmj.324.7353.1545

Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: An evidence-based review. Drugs. 2007; 67: 887- 901. DOI: https://doi.org/10.2165/00003495-200767060-00005

Miler MR., Hankinson J., Brusasco V et al. Standardisation of spirometry. Eur Respir J. 2005;26:319-338. DOI: https://doi.org/10.1183/09031936.05.00034805